Aspirin component holds promise for treating Alzheimer's
A component of aspirin can block a cell death associated with neurodegenerative diseases like Alzheimer's, Parkinson's and Huntington's disease, a new study says.
Aspirin binds to an enzyme called GAPDH which is believed to play a major role in neurodegenerative diseases.
"The enzyme GAPDH, long thought to function solely in glucose metabolism, is now known to participate in intra-cellular signaling," said study co-author Solomon Snyder, professor of neuroscience at Johns Hopkins University in Baltimore.
"The new study establishes that GAPDH is a target for salicylate drugs related to aspirin and hence may be relevant to the therapeutic actions of such drugs," he noted.
The salicylic acid is the primary breakdown product of aspirin.
"A better understanding of how salicylic acid and its derivatives regulate the activities of the key protein can lead to the development of new and better salicylic acid-based treatments of a wide variety of devastating diseases," Klessig explained.
"A better understanding of how salicylic acid and its derivatives regulate the activities of GAPDH and HMGB1, coupled with the discovery of much more potent synthetic and natural derivatives of salicylic acid, provide great promise for the development of new and better salicylic acid-based treatments of a wide variety of prevalent, devastating diseases," said Klessig.
Aspirin binds to an enzyme called GAPDH which is believed to play a major role in neurodegenerative diseases.
"The enzyme GAPDH, long thought to function solely in glucose metabolism, is now known to participate in intra-cellular signaling," said study co-author Solomon Snyder, professor of neuroscience at Johns Hopkins University in Baltimore.
"The new study establishes that GAPDH is a target for salicylate drugs related to aspirin and hence may be relevant to the therapeutic actions of such drugs," he noted.
The salicylic acid is the primary breakdown product of aspirin.
"A better understanding of how salicylic acid and its derivatives regulate the activities of the key protein can lead to the development of new and better salicylic acid-based treatments of a wide variety of devastating diseases," Klessig explained.
"A better understanding of how salicylic acid and its derivatives regulate the activities of GAPDH and HMGB1, coupled with the discovery of much more potent synthetic and natural derivatives of salicylic acid, provide great promise for the development of new and better salicylic acid-based treatments of a wide variety of prevalent, devastating diseases," said Klessig.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.